Tolerância nasal com a proteína colágeno V reverte o remodelamento no eixo broncovascular na bronquiolite obliterante experimental by Garippo, Ana et al.
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INTRODUCTION: The precise role of the remodeling process and possible therapies for bronchiolitis obliterans remain to be
established.
OBJETIVE: In the present study, we sought to validate the importance of nasal collagen V tolerance to verify whether bronchovascular
axis remodeling could be reverted by this therapeutic approach when compared to steroid treatment.
METHODS: Mice were randomly divided into 4 groups: control, bronchiolitis obliterans, collagen V tolerance, and prednisone
groups. Morphometry was employed to evaluate bronchovascular axis dimensions, collagen density, and immune cell response.
Collagen V nasal tolerance and steroid-treated mice showed significantly lower values of terminal bronchiole wall thickness and
reduction in peribronchovascular cells; bronchioalveolar lymphoid tissue; and CD3+, CD4+, CD8+, and CD20+ lymphocytes. A
significant decrease in CD68+ macrophage density was found in prednisone-treated mice. In addition, a strong quantitative relationship
was found between collagen V tolerance, and reduction in density of immune cells and collagen.
RESULTS: Our results indicate that bronchovascular axis remodeling in bronchiolitis obliterans can be reverted by collagen V
nasal tolerance, possibly as the result of T-cell suppression.
CONCLUSION: We concluded that the tolerance effects in this model were strongly related to the improvement in bronchovascular
remodeling, and these may be an appropriate targets for further prospective studies on nasal collagen V tolerance.
KEYWORDS: Bronchiolitis obliterans.Chemical injury. Nasal immunization. Collagen V. Morphometry.
INTRODUCTION
Only a few patients with brochovascular axis remodeling
process following bronchiolitis obliterans respond to treat-
ment.1 The recognition of possible pathological mechanisms
involved in the manifestation of bronchiolitis obliterans might
help establish the adequate treatment or definitively block
lung remodeling. Thus, the understanding of the mechanisms
in bronchiolitis obliterans remodeling and the treatment ef-
fects aiming at preventing irreversible damage and decreased
survival are of great interest. Although the exact mechanism
of the steroid treatment effect remains unknown, steroid treat-
ment seems to diminish the affluence of immune inflamma-
tory cells and their mediators in animal models of bronchi-
olitis obliterans, thus affecting collagen synthesis and deg-
radation, interfering with the remodeling of the extracellu-
lar matrix. Because active remodeling of the extracellular
matrix has been thought to be important in prompting
bronchovascular axis restoration, a group of collagens have
also been targeted as potentially useful indicators.2
Collagen V is a component of the extracellular ma-
trix located in the bronchovascular interstitium, septal
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interstitium, and capillary basement membranes and is
surrounded by vascular smooth cells.3,4 It is a very pre-
served protein found in many different animal species,
and it maintains the NH2 terminal end, making this mol-
ecule more immunogenic.5 Normally, this protein is not
found exposed in the extracellular matrix, as it is hid-
den among collagen types I and III, composing hetero-
typic fibers.4,5 Collagen V tolerance has shown promis-
ing results in experimental lung allograft rejection, pre-
venting bronchovascular axis remodeling.6,7 Other clini-
cal studies have also shown that oral tolerance induced
by collagen I, II, and IV has meaningful clinical efficacy
in rheumatoid arthritis,8–10 systemic sclerosis,11 and
glomerulonephritis.12
Recently, we have shown an important inflammatory re-
sponse in bronchiolitis obliterans produced by chemical in-
jury, followed by remodeling of the bronchovascular axis.13
The aim of promoting mucosal tolerance is to suppress
specific immune reactivity without affecting the entire im-
munological system by deleting or inactivating specific an-
tigen-driven T-cell clones. We have recently reported im-
mune cell infiltration and broncovascular axis remodeling
after nasal instillation of nitric acid in a mouse model of
bronchiolitis obliterans.13 In the present study, we proposed
to establish nasal tolerance with collagen V protein in an
attempt to ascertain whether the main aspects of bronchi-
olitis obliterans, including bronchovascular axis
remodeling, could be reverted by this therapeutic approach.
To evaluate the significance of the effect of nasal tolerance
with collagen V protein in bronchiolitis obliterans, we also
assessed the effect of steroid treatment on bronchovascular
axis remodeling.
MATERIALS AND METHODS
Experimental groups
Forty normal female BALB/c mice (4-6 weeks old and
17-26 g) were randomly divided into 4 groups: (i) in the
control group, animals did not undergo any procedures
(CTRL, n = 10); (ii) in the bronchiolitis obliterans group
(BO, n = 10), mice received a single nasal instillation of a
solution of 4.8 mmol/mL of HNO3 2%, pH 0.1, as previ-
ously described;13 (iii) nasal tolerance was induced in the
animals with 8 weeks of bronchiolitis obliterans by daily
nasal administrations of 20 ml (0.5 mg/mL/animal/day) col-
lagen V for 7 days and, subsequently, after 30 days on al-
ternate days7 (BO + COLV-TOL group; n = 10); (iv) ani-
mals with 8 weeks of bronchiolitis obliterans were treated
with 0.002 mg/animal/day of prednisone for 7 days (BO+PR
group; n = 10). Figure 1 shows the experimental design.
Animal preparation
At the end of the experiments, animals were anaesthe-
tized with an intraperitoneal injection of ketamine 1 mL,
xylazine 0.25 µl suspended in 3.75 mL saline solution at a
concentration of 0.015 mL/g body weight. The animals
were exsanguinated, and the thoracic and abdominal cavi-
ties were opened and the lungs removed in bloc.
All mice received humane care in compliance with the
“Guide for care and use of laboratory animals” (NIH pub-
lication 85-23, revised 1985). The study was approved by
the institutional review board of our institution, the Coun-
cil for Research of the School of Medicine, University of
São Paulo (CAPPesq).
Lung histology
Sections representing peripheral areas of the lung were
cut and subsequently fixed with 10% formaldehyde for 24
h. After fixation, tissues were paraffin-embedded. Histologi-
cal sections (3 mm in thickness) were cut and stained with
hematoxylin and eosin (H&E) and were evaluated by re-
searchers blinded to the protocol design. As previously de-
scribed,10 bronchiolitis obliterans was histologically char-
acterized by bronchovascular axis remodeling that resulted
in reduction or total obliteration of the terminal bronchi-
ole lumen, increased wall thickness, deposition of collagen
fibers at the peribronchovascular extracellular matrix, and
immune cell infiltration.
To evaluate the deposition of collagen fibers at the
peribronchovascular axis, collagen was stained in a 0.2%
solution of Sirius red (Direct Red 80, C.I. 35780, Aldrich,
Milwaukee, WI) dissolved in a saturated aqueous solution
Figure 1 - Experimental Design: (i) group (CTRL): no procedures; (ii)
bronchiolitis obliterans group (BO): single nasal HNO3 solution instillation;
(iii) nasal tolerance group (BO+COLV-TOL): induced after 8 weeks of
bronchiolitis obliterans by daily nasal administrations of collagen V (7 days)
and, subsequently, after 30 days on alternate days; (iv) bronchiolitis obliterans
+ prednisone group (BO+PR): after 8 weeks of bronchiolitis obliterans,
treated with 0.002 mg/animal/day of prednisone for 7 days. At the end of
experiments, (13 weeks), lungs were removed and histologically processed.
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of picric acid, and observed under polarized light
microscopy.
Immunohistochemistry analysis was used to evaluate
immune cell airway infiltration of the bronchovascular axis
as previously described.13 For the immune cell infiltration
markers, we used the following antibodies: CD20, B-Cell
(Clone L26, Dako Corporation Carpinteria, USA, 1:600);
CD3 (Leu-4, T3, 1:600), T-Cell CD4 (CD45RO, clone
OPD4, 1:400); CD8 T-Cell (Clone C8/144B, 1:100); Mac-
rophage, CD68 (Clone KP1, 1:3200), Neutrophil Elastase
(Clone NP57, 1:800) from Dako A/S Denmark. A second-
ary procedure using the VECTASTAIN® ABC kit (Vector
Technologies, Burlingame, CA), which produces a
streptavidin-biotin complex, was then performed.
The area of the terminal bronchiole and artery lumen
was expressed in µm2 and comprised the area of wall thick-
ness, including the internal border lumen, epithelial cell
height, and basement membrane extending to the outer
smooth muscle border. The wall thickness of the terminal
bronchiole and artery was determined by the difference be-
tween the total area and the lumen area in µm2. Immune
cell infiltration was evaluated by determining the presence
of bronchiole-associated lymphoid tissue (BALT); CD3+,
CD4+, CD8+, and CD20+ lymphocytes; CD68+
macrophages; neutrophils; and total cells. Collagen density
and immune cell infiltration were expressed as percentages.
Morphometric analysis was performed to evaluate the ex-
tent and distribution of histological changes that resulted in
bronchiolitis obliterans after bronchovascular axis remodeling.
The bronchovascular axis includes the terminal bronchiole,
terminal artery, and correspondent extracellular matrix. These
were measured regarding diameter, wall thickness, collagen,
and immune cell densities using an image analysis system
(LEICA Qwin Imaging Systems Ltd., Cambridge, England).
The terminal bronchiole and artery diameter present in
each sample at (x100) and (x400) magnification, respec-
tively, were measured in 10 random noncoincident micro-
scopic fields using the lengths of the total and transversal
areas when the minimum and maximum diameter ratio was
greater than 0.6. The wall thickness of the terminal bron-
chiole and artery was determined by the difference between
the total area and the lumen area in mm2. Immune cell in-
filtration was evaluated for the presence of bronchiole-as-
sociated lymphoid tissue (BALT); CD3+, CD4+, CD8+, and
CD20+ lymphocytes; CD68+ macrophages; neutrophils; and
total cells. Collagen density and immune cell infiltration
were expressed as percentages.
Statistical analysis
Measurements were expressed as mean ± standard de-
viation. All statistical procedures were performed using
SPSS software v.13.0 (SPSS, Inc., Chicago, IL 2004). Data
were assessed by t test and ANOVA with Tukey-HSD or
Dunnett-T3 post-hoc tests for multiple comparisons. A P
value less than .05 was considered statistically significant.
RESULTS
Lung histology
Figure 2 shows the bronchovascular axis (terminal bron-
chiole and matched artery) in the control (CTRL), bron-
chiolitis obliterans (BO), nasal tolerance with collagen V
(BO + COLV-TOL), and prednisone-treated (BO+PR) ani-
mals. Tissue is shown treated with H&E stain, picrosirius
red under polarized light microscopy, and an immunohis-
tochemical reagent (CD3). In control mice, the
bronchovascular axis architecture is preserved, and there
is a weak red-orange birefringence of bronchovascular axis
tissue sections, coincident with the maintenance of the
peribronchovascular extracellular matrix density. In con-
Figure 2 - Lung histology from the CTRL, BO, BO+COL-TOL, BO+PR
groups respectively, stained with H&E and picrosirius, observed under
polarized light microscopy, with immunohistochemistry for CD3+. CTRL
lungs showed reddish birefringence of bronchovascular extracellular matrix,
maintenance of lumen and histoarchitecture of terminal bronchiole in H&E
preparations. BO lungs showed obliteration or distortion of terminal
bronchiole lumen, major immune cell infiltration, and wall distortion, with
diffuse increase of birefringence around the periadventitial extracellular
matrix. Note intensity of histoarchitecture modification, lumen and immune
cell infiltration, with decreased birefringence around periadventitial
extracellular membrane in terminal bronchiole of BO+PR and BO+COL-
TOL lungs. TB- terminal bronchiole and TA- terminal artery, 400x.
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trast, bronchiolitis obliterans animals show a distortion of
the bronchovascular axis, with reduction or total oblitera-
tion of the lumen, diffuse increase of birefringence, and in-
tense immune cell infiltration in the peribronchovascular
extracellular matrix, shown in H&E preparations. Pred-
nisone and collagen V treatments induce a remarkable res-
toration of the bronchovascular axis architecture and de-
crease collagen deposition and immune cell infiltration
around the bronchovascular axis, which is more intense in
animals induced to nasal tolerance with collagen V.
The extension and distribution of the lesions along the
bronchovascular axis differed in quantitative terms accord-
ing to the animal group.
Measurements of the terminal bronchiole, terminal ar-
tery, peribronchovascular collagen, and immune cells are
shown in Table 1 and illustrated in Figures 3A-C and 4A-C.
Both collagen V and prednisone treatments affect the
wall thickness of the bronchovascular axis (terminal bron-
chiole and artery) (Figure 3A). Reductions were found in
the following parameters in the COLV-TOL group com-
pared with the BO group: terminal bronchiole wall thick-
ness (P = .002); collagen density in the terminal bronchi-
ole (P = .01, Figure 3B); density of peribronchovascular
cells (P = .002); density of BALT in both the terminal bron-
chiole and the matched artery when compared to bronchi-
olitis obliterans animals (P = 0.002 and P = .01, respec-
tively, Figure 3C); density of CD3+ cells (P = .03, Figure
4A); density of CD20+ cells (P = .005, Figure 4A); and den-
sity of CD4+ cells (P = .001, Figure 4B). Notable was the
increase in density of CD8+ cells after collagen V and pred-
nisone treatments when compared with control animals (P
= .004 and P = .01, respectively, Figure 4B). Densities of
CD68+ cells and neutrophils, which were increased in the
BO group, did not differ between the collagen V nasal tol-
erance and prednisone groups (Figure 4C). The total cell
density decreased along the bronchovascular axis after col-
lagen V nasal treatment (P = .003).
Inter- and intra-observer comparisons were performed
in 20% of the slides by 2 observers (ALG and ERP) or by
doubling the time of the same observer. The coefficient of
variation for the inter- and intra-observer was less than
5%.error
DISCUSSION
Systemic steroids have been widely employed for infants
with acute viral bronchiolitis and young children with acute
viral bronchiolitis or adults with bronchiolitis obliterans af-
ter transplantation, but the actual benefit of this interven-
tion requires clarification.14,15 In 13 studies involving 1,198
affected children, no benefits were found for duration of
hospital stay, clinical score, or other outcomes.
Patel et al16 demonstrated that no benefits were found
in either bronchiolitis or clinical score in infants and young
children treated with systemic steroids as compared with
placebo. In addition, marked study heterogeneity and oc-
casionally, conflicting direction of benefit between trials
suggest that these results should be interpreted with cau-
Table 1 - Measurements of terminal bronchioles, terminal arteries, peribronchovascular collagen, and immune cells in the
4 experimental groups of animals (mean ± SD).
CTRL BO BO + COLV-TOL BO + PR
TB diameter (µm) 0.83 ± 0.05 0.79 ± 0.07 0.83  ± 0.06 0.77 ± 0.06
TB wall thickness (µm2) 18.35 ± 4.90*# 27.06 ± 6.39*# 19.09 ± 2.75# 21.76 ± 3.68#
TA diameter (µm) 0.86 ± 0.05 0.84 ± 0.06 0.83 ± 0.08 0.80 ± 0.03
TA wall thickness (µm2) 3.39 ± 0.82 3.90 ± 0.97 3.16 ± 1.18 6.87 ± 4.29
TB collagen (%) 4.61 ± 0.73 7.28 ± 4.25# 2.05 ± 1.31# 4.54 ± 1.83
TA collagen (%) 24.09 ± 6.91 23.11 ± 9.08 12.57 ± 4.57 18.39 ± 7.16
TB cells (%) 6.60 ± 1.97*   25.30 ± 7.04*# 7.50 ± 3.92# 22.58 ± 9.53
TA cells (%) 8.14 ± 1.65#    30.72 ± 11.89# 9.93 ± 4.15# 32.89 ± 13.64
BALT cells (%) 6.23 ± 3.64*    34.65 ± 4.41*# 15.24 ± 7.54# 27.32 ± 16.68*
CD3+ lymphocytes (%) 16.40 ± 4.38    31.37 ± 10.91# 14.52 ± 11.13# 14.55 ± 4.70#
CD4+ lymphocytes (%) 1.23 ± 1.05* 15.87 ± 6.89* 0.44 ± 0.48* 20.74 ± 6.70
CD8+ lymphocytes (%) 1.11 ± 1.07# 9.01 ± 5.97 3.15 ± 3.68# 14.39 ± 7.37#
CD20+ lymphocytes (%) 1.46 ± 1.89# 16.17 ± 5.35# 1.98 ± 1.87# 15.36 ± 9.74
CD68+ macrophage (%) 0.24 ± 0.28* 15.80 ± 4.33* 9.05 ± 5.96* 11.70 ± 13.52
Neutrophils (%) 0.52 ± 0.84# 2.46 ± 1.32 3.54 ± 2.33# 6.06 ± 4.26#
Total cells (%) 20.97 ± 2.92*   90.68 ± 20.24*# 32.68 ± 13.55# 82.80 ± 34.49
Abbreviations: BALT- bronchiolar associated lymphoid tissue; BO- bronchiolitis obliterans; BO + COLV-TOL- bronchiolitis obliterans + nasal
tolerance with type V collagen; BO+PR- bronchiolitis obliterans + prednisone treatment; BV- bronchovascular axis; CTRL- control; TA- terminal artery;
TB- terminal bronchiole; Statistical comparisons- ANOVA with Tukey-HSD or Dunnett-T3 post hoc test  were compared bronchiolitis obliterans with
other groups: *P = .001 and #P < .05
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Figure 3- Quantitative data of TB wall thickness (A), expressed in µm2.
Collagen density (B) and bronchovascular axis immune cells (C), expressed
in (%). Decreased TB area and wall thickness seen in BO+COLV-TOL
animals compared to the BO group. Collagen density (B) in TB decreased
in the BO+COLV-TOL group compared to BO. Peribronchovascular cell
density (D) in TB and matched artery reduced in BO+COLV-TOL animals
compared to BO. TB- terminal bronchiole; TA- terminal artery.
Figure 4 - Quantitative data of densities (%) of CD3+ and CD20+ (A), CD4+
and CD8+ (B), and CD68+ and macrophage (C) immune cells in CTRL, BO,
BO+COLV-TOL and BO+PR lungs. Compare CD3+ cells for TB (A) from
BO+COLV-TOL and BO+PR to BO animals. CD20+ (A) and CD4+ (B) cells
reduced after BO+COLV-TOL, when compared to BO. Note increase in
CD8+ cells (B) in animals receiving the BO+COLV-TOL and BO+PR
treatments, vs. CTRL. Density of CD68+ cells and neutrophils, increased in
BO lungs, did not differ between the BO+COLV-TOL and BO+PR (C). TB-
terminal bronchiole, TA- terminal artery; BO- (bronchiolitis obliterans).
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tion. The variable response to anti-inflammatory treatment
could be attributed to the heterogeneous biochemical and
molecular mechanisms activated in response to different
initial insults.17,18 Moreover, the inflammatory mechanisms
are continuous and cyclic, sometimes causing deterioration
or improvement in lung function. Other major continuing
problems include determining when to administer pred-
nisone, monitoring its use, and determining what other
therapy it should be compared with.16 Hence, the aim of the
present study was to compare collagen V nasal tolerance
with a traditional therapeutic approach, such as prednisone,
in an experimental bronchiolitis obliterans model.
Clearly, the likely reason for failure of treatment to cure
some patients with bronchiolitis obliterans is due to the ir-
reversible scarring of the bronchovascular axis, which is
not detected by either routine imaging or routine pathologi-
cal analysis.
The question of interest is whether additional, more
technological information obtained from histopathological
assessment can help us identify patients with bronchiolitis
obliterans who are likely to present scarring of the
bronchovascular axis and, consequently, poor response to
treatment, thus helping improve long-term function and
prevent the cumulative morbidity.19
The inflammation/repair processes that occur in bron-
chiolitis obliterans undoubtedly comprise a series of com-
plex, sequential steps; however, among these, the immune
system is thought to be especially important, due to its in-
teraction with the extracellular matrix remodeling.15
Type V collagen fulfills all the criteria of a fibrillar col-
lagen: both N- and C-termini are processed, and it consists
of an approximately 1000-amino acid chain, thus control-
ling fibrillogenesis and making it more immunogenic.20
Despite being a quantitatively minor collagen, collagen
V is fundamental not only for regulation of fibril diameter
of other collagen types, but also for the integrity of con-
nective tissues.21 Whereas prior studies4–7 were able to show
a significant relationship between lung transplantation and
collagen V tolerance, our results suggested that nasal col-
lagen V tolerance could be used to interrupt the bronchi-
olitis obliterans process, reducing collagen deposition and
T- and B-cell reactivity.
Although the precise mechanisms for daily sampled an-
tigens in the bronchial epithelia induction are still unclear,
collagen V treatment of lung diseases that develop with fi-
brosis may be promising. Presumably, when collagen V im-
munization is carried out by the nasal route, it may reach
the lymphoid tissue associated with the nasal mucosa, where
it is processed and then locally presented to T cells so they
can induce pro-inflammatory as well as suppressive immune
responses4–7 in the pre-acinar axis.
In a variety of situations, oral and nasal induction to
collagen may stabilize experimental,8,22 and human arthri-
tis,10 systemic sclerosis,23and osteoarthrosis.24
Our data are both interesting and important and con-
tinue the studies of Dr. David Wilkes’ group, which have
previously documented that collagen V-induced oral toler-
ance prevents bronchiolitis obliterans after rat lung
allografts.4–7
Considering these facts, we were not be surprised to
learn that collagen V nasal tolerance could revert the
bronchovascular axis remodeling in bronchiolitis obliterans,
and our results have now confirmed the importance of this
therapeutic approach.
A beneficial effect of low doses of orally or nasally ad-
ministered collagen types I and II has also been demon-
strated as an immunotherapeutic intervention for arthritic
joints.8–10
We have also observed that collagen V and prednisone
treatments reduced peribronchovascular cells and BALT in
both the terminal bronchiole and matched artery when com-
pared to control animals.
Regarding collagen fibers in the terminal bronchiole, we
observed that collagen V treatment resulted in a decrease
in this response compared with control animals. Most in-
teresting was the strong, quantitative relationship observed
between tolerance and reduction in density of immune cells
and collagen. Although a variety of associations between
prednisone and lung remodeling have been described re-
cently,15,25 we observed that its relationship with immune
cells and collagen density was not as strong as that observed
for collagen V tolerance.
In fact, we found that collagen V treatment reduced den-
sities of CD3+, CD4+, CD20+, and CD68+ cells. Not only
has tolerance been thought to dramatically reduce immune
cell response and thus protect the host from deleterious
cytokine effects, but it has also been thought to regulate ex-
tracellular matrix synthesis and degradation.8
Of interest was our finding of an increase in density of
CD8+ lymphocytes in animals with untreated bronchiolitis
obliterans when compared with control animals and a de-
crease after collagen V treatment, suggesting that collagen
V nasal tolerance induces significant, prompt restoration
of the bronchovascular axis, possibly as the result of T-cell
suppression. It has been postulated that CD8+ T suppres-
sor cells can be induced by exposure to an antigen.
When stimulated, CD8+ T suppressor cells also suppress
immune system responses. The B-cell population is “toler-
ated” through clonal deletion, anergy and/or sequestering
of antigens within an organ.26 Where T-cell help is required
to activate B cells exposed to thymus-dependant antigens,
suppression of the T helper CD4+ cell population will pre-
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vent possible autoantibody production.27,28 It is well known
that a decrease in B- and T-cell reactivity induced by col-
lagen V tolerance can prevent bronchiolitis obliterans in
lung transplantation.4,29
At present, we have demonstrated that there is an asso-
ciation between tolerance and reduction in immune cell in-
filtration and restoration of the bronchiole dimension in
bronchiolitis obliterans caused by chemical injury. Thus,
decreased immune cell infiltration may be more of a pri-
mary event, and bronchovascular axis remodeling, more of
a secondary event. Regardless of the mechanism, immune
cell infiltration and collagen density provide important mor-
phological information in experimental bronchiolitis oblit-
erans.
Finally, randomized and prospective trials will be re-
quired, since we believe it is important to validate our thera-
peutic assessment of collagen V nasal tolerance as well as
to extend it to other lung diseases by studying additional
patients. We conclude that the effects of collagen V nasal
tolerance in bronchiolitis obliterans induced by chemical
injury were strongly related to the improvement in
bronchovascular axis remodeling. Lungs with increased
immune cell and collagen density around the
peribronchovascular axis comprise a subset with a high risk
of irreversible scarring and may be an appropriate target
for prospective studies of collagen V tolerance. The colla-
gen V therapeutic approach may be especially important
in patients who are resistant to steroids.
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RESUMO
Garippo A; Parra E; Teodoro W; Rivero D; Souza F;
Yoshinari N; Capelozzi V. Tolerância nasal com a proteína
colágeno V reverte o remodelamento no eixo bronco-
vascular na bronquiolite obliterante experimental.
CLINICS. 2007;62(4):499-506.
INTRODUÇÃO: A participação precisa do processo de
remodelamento e possíveis implicações no tratamento da
bronquiolite obliterante ainda não está estabelecida.
OBJETIVOS: Estabelecer a importância da tolerância na-
sal induzida pelo colágeno do tipo V e verificar se o pro-
cesso de remodelamento do eixo broncovascular pode ser
revertido com esta estratégia terapêutica comparada ao efei-
to do tratamento com esteróides.
MATERIAL E MÉTODO: Camundongos foram divididos
em quatro grupos: controle, bronquiolite obliterante, tolerân-
cia nasal com colágeno do tipo V e prednisona. Morfometria
foi realizada para avaliar as dimensões do eixo broncovas-
cular, densidade de colágeno e resposta imunocelular. Ca-
mundongos submetidos à tolerância nasal com colágeno do
tipo V e tratados com prednisona exibiram significativas re-
duções da espessura da parede de bronquíolos terminais, da
densidade de células inflamatórias ao redor do eixo
peribroncovascular e da resposta imunocelular às custas de
linfócitos CD3, CD4, CD8 e CD20. Houve também signifi-
cativa redução da densidade de macrófagos CD68 nos ca-
mundongos tratados com prednisona. Adicionalmente, hou-
ve uma forte associação entre tolerância nasal induzida pelo
colágeno do tipo V, resposta imunocelular e redução do con-
teúdo de colágeno peribroncovascular.
RESULTADOS: O remodelamento do eixo broncovascular
na bronquiolite obliterante pode ser revertido pela indução
de tolerância nasal com o colágeno do tipo V, possivelmen-
te como resultado de supressão de linfócitos T.
CONCLUSÃO: Os efeitos da tolerância nasal no presen-
te modelo estiveram fortemente relacionados à melhora no
remodelamento do eixo broncovascular, despontando como
um alvo promissor para estudos prospectivos.
UNITERMOS: Bronquiolite obliterante. Lesão química.
Imunização nasal. Colágeno V. Morfometria.
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